Refine your search

Search Results within category "Lung Disease & Asthma"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Lung Disease & Asthma"


9 Study Matches

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

This study is for patients 40-80 years of age with IPF (idiopathic pulmonary fibrosis). This study is being done to learn more about an experimental medication which is being developed to treat fibrosis or scarring of the lungs. The purpose of this study is to evaluate the safety of this experimental medication when administered at two dose levels compared with placebo (injection containing no active medication).
Donna Griffiths at dgriffiths@pennstatehealth.psu.edu or 717-531-5519
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03538301
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 40-80 years of age
Have a diagnosis of IPF within the past 5 years
Unchanged dose of pirfenidone or nintedanib for at least 12 weeks if currently taking these medications
Exclusion Criteria:
Respiratory exacerbation or hospitalization in the last 3 months
Taking both pirfenidone and nintedanib simultaneously in the past 12 weeks
Lung transplant anticipated during the study
Known history of liver cirrhosis
Active smoker or cessation in the past 12 weeks
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

This is a drug study, that will evaluate the potential effectiveness of an investigational drug called pamrevlumab, compared to a placebo, in patients diagnosed with Idiopathic Pulmonary Fibrosis.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03955146
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 40 to 85 years
Diagnosis of Idiopathic Pulmonary Fibrosis
Impaired Pulmonary Function Test Results
Exclusion Criteria:
Diagnosed Obstructive Lung Disease
Nursing or pregnant females
Currently smoking
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For VIOLET

Site For VIOLET
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 717-531-1707, ext=3
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Admission to ICU with acute risk factors for Acute Respiratory Distress Syndrome (ARDS): Pneumonia, Aspiration, smoke inhalation, lung contusion, hypoxemia, intubation
shock
sepsis
pancreatitis
Vit. D deficiency
Exclusion Criteria:
unable to take Vit D by mouth
blood Calcium levels > 10.2
known kidney stone in past 1 year
Do Not Rescusitate orders (DNR)
prisoner
Infectious Diseases & Immune System, Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Effects of antibiotic use on fecal microbiome and resistome

This study will investigate the changes in the human fecal microbiomes and resistomes in response to antibiotic treatment.
Jasna Kovac at jzk303@psu.edu or 814-699-1680
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
over age 18
English speaking/reading
Books a medical appointment for upper respiratory tract infection
Exclusion Criteria:
Patient took antibiotics in the past week
Patient participated in STUDY00012891 previously
Reason for medical visit is not upper respiratory tract infection
Patient is pregnant
Patient has a medical history that includes diagnosis of any intestinal related disease
Infectious Diseases & Immune System, Lung Disease & Asthma
  Email this study information to me
  Contact the study team

Evaluating the Cough Reflex in Fibrotic and Healthy Lungs

Determining cough threshold in patients with fibrotic lung disease and in healthy controls by stimulating cough.
Timothy Sheehan at tsheehan@pennstatehealth.psu.edu or 717-531-2925
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
40 years of age or older
Patient Group: Fibrotic lung disease with chronic cough symptoms or Idiopathic cough syndrome
Healthy Control Group: no cough (either chronic or acute)
Exclusion Criteria:
Recent history of smoking (former smokers must be tobacco-free for at least 1 year)
History of (other) lung diseases
History of uncontrolled gastroesophageal reflux disease (GERD)
Use of exclusionary medications (i.e. steroids, ACE inhibitors, narcotics, cough suppressants)
History of uncontrolled post nasal drip
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis

This study is for patients with IPF (Idiopathic Pulmonary Fibrosis) to see how well a new medication works with current standard treatment on lung function and IPF disease in general.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03711162
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 40 or greater
Diagnosis of Idiiopathic Pulmonary Fibrosis (IPF) within the past 5 years
Exclusion Criteria:
HIV or hepatitis B or C diagnosis
History of malignancy within the past 5 years
Acute IPF reoccurrence in the past 6 months
Lower respiratory tract infection in the past 4 weeks requiring antibiotics
History of lung volume reduction surgery or lung transplant
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Recruitment for Nicotine and Tobacco Related Research at Penn State Hershey

The purpose of this project is to screen potential participants for multiple research studies being conducted by tobacco researchers at Penn State Hershey. Since there are multiple IRB approved studies enrolling at Penn State Hershey with similar but not identical inclusion/exclusion criteria, it is more efficient for the researchers and participants to have one phone number to call initially for basic screening. After completing this, the participant can be redirected for more specific screening if they are found to be potentially eligible for one of the studies.
Candace Bordner at cbordner@phs.psu.edu or 844-207-4594
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 21 or older
Current tobacco user
Exclusion Criteria:
Age less than 21
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse, Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 3 locations

Study Locations

Hide all locations
Location
Harrisburg, PA
Hershey, PA
York, PA

A Survey to Estimate the Socio-Economic Impact of the Novel Corona Virus (COVID-19) Pandemic

We are experiencing global outbreak of coronavirus (COVID-19) recently. Millions of people are suffering and dying every day, in spite of putting our best efforts. We are doing this survey to understand people’s reaction to this situation. The survey will ask about your knowledge, practices and worries. Your response will help us to understand how to better control these situations. Your feedback is highly important to us, as we need to find out the best way to stop the disease from spreading and killing thousands of lives, and to reduce the stress among the population.
Pritish Mondal at pmondal@pennstatehealth.psu.edu or 717-897-0652
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
General population
Adult
Exclusion Criteria:
Age below 18 years
Mentally impaired
Participants from Europe or European Union (EU)
Infectious Diseases & Immune System, Prevention, Lung Disease & Asthma
  Email this study information to me
  Contact the study team

A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF)

Assessment of the safety and tolerability of PLN-74809 following daily administration for up to 28 days in patients with idiopathic pulmonary fibrosis
Donna Griffiths at dgriffiths@pennstatehealth.psu.edu or 717-531-5519
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT04396756
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged 50 years or older
Idiopathic Pulmonary Fibrosis (IPF) diagnosis
Exclusion Criteria:
Receiving non-approved agents to treat IPF
Need for continuous oxygen supplementation >15 hours/day
Active lung or sinus infection
Active smoker
Hepatic impairment or end-stage liver disease
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA